within Pharmacolibrary.Drugs.ATC.J;

model J05AX29
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.26,
    Cl             = 17.9 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 600 / 1000000,
    adminCount     = 1,
    Vd             = 0.189,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0105,
    Tlag           = 15.0
  );

  annotation(Documentation(
    info ="<html><body><p>Fostemsavir is an antiretroviral medication used for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection for whom an otherwise suppressive antiretroviral regimen is not available. It is a prodrug of temsavir, which acts as an attachment inhibitor binding to gp120 on HIV-1, preventing virus attachment and entry into host CD4+ cells. Fostemsavir is FDA- and EMA-approved.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetics of temsavir (the active moiety of fostemsavir) in HIV-1-infected adults, following oral administration of fostemsavir 600 mg twice daily.</p><h4>References</h4><ol><li><p>Chahine, EB (2021). Fostemsavir: The first oral attachment inhibitor for treatment of HIV-1 infection. <i>American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists</i> 78(5) 376–388. DOI:<a href=&quot;https://doi.org/10.1093/ajhp/zxaa416&quot;>10.1093/ajhp/zxaa416</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33547469/&quot;>https://pubmed.ncbi.nlm.nih.gov/33547469</a></p></li><li><p>Magee, M, et al., &amp; Moore, K (2021). Effect of Renal and Hepatic Impairment on the Pharmacokinetics of Temsavir, the Active Moiety of Fostemsavir. <i>Journal of clinical pharmacology</i> 61(7) 939–953. DOI:<a href=&quot;https://doi.org/10.1002/jcph.1810&quot;>10.1002/jcph.1810</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33368327/&quot;>https://pubmed.ncbi.nlm.nih.gov/33368327</a></p></li><li><p>Nwokolo, N, et al., &amp; Moore, K (2023). Fostemsavir and ethinyl estradiol drug interaction: Clinical recommendations for co-administration. <i>HIV medicine</i> 24(5) 580–587. DOI:<a href=&quot;https://doi.org/10.1111/hiv.13442&quot;>10.1111/hiv.13442</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/36372442/&quot;>https://pubmed.ncbi.nlm.nih.gov/36372442</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end J05AX29;
